Tariffs drive $400B+ US investment as pharma R&D shifts to AI-guided automated discovery
HealthcareAIGuy · x · 2026-09-24
The author highlights an inflection point: pharma R&D is shifting toward AI-guided, increasingly automated drug discovery.
Tariffs and supply chain pressure are driving $400B+ in US manufacturing and R&D investment — creating a reset moment for lab design and a major testbed for AI in real scientific workflows.
More from Venture
- Prototyping.io raises $6.2M seed round for its AI prototyping tool — ycombinator · 2026-09-25
- Jensen Huang: 80% of $400B in Recent AI Startup Funding Relies on Open Models — markjeffrey · 2026-09-25
- Index My Site adds automatic sitemap.xml indexing with filters; fast mode and Bing support coming — iannuttall · 2026-09-25
- Higgsfield crosses $1B annualized revenue 18 months after launch, 30M users — SimplyAnnisa · 2026-09-25
- Anthropic staffer's startup tip: build things that save agents tokens — jeff_weinstein · 2026-09-25
- Nvidia to buy $1.5B more SB Energy shares pre-IPO, lifting stake to $3B — Beth_Kindig · 2026-09-25